Finanzen von Lakefront Biotherapeutics NV (LKFT)LKFTLakefront Biotherapeutics NV

Evaluating the bottom line, Lakefront Biotherapeutics NV maintains a gross margin of 24.48%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -359.30%, while the net margin is 16.05%. These profitability ratios, combined with a Return on Equity (ROE) of 20.12%, provide a clear picture of how effectively LKFT converts its operational activities into shareholder value.

In the context of the broader market, LKFT competes directly with industry leaders such as XERS and XNCR. With a market capitalization of $2.10B, it holds a significant position in the sector. When comparing efficiency, LKFT's gross margin of 24.48% stands against XERS's 83.47% and XNCR's 100.00%. Such benchmarking helps identify whether Lakefront Biotherapeutics NV is trading at a premium or discount relative to its financial performance.

Lakefront Biotherapeutics has shown a significant increase in total revenue, with Q4 2025 revenue reaching 900822000 EUR, and gross margin peaking at 99.95% in Q4 2025, indicating strong profitability potential.